Status:
RECRUITING
Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study
Lead Sponsor:
Thammasat University
Conditions:
COPD
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
40-80 years
Phase:
PHASE4
Brief Summary
The goal of this clinical trial is to determine if triple inhaled therapy with Budesonide/Glycopyrronium/Formoterol (BGF) and Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) are effective in treatin...
Detailed Description
This study is a randomized crossover study. COPD patients aged 40 years or older with stable disease are included. Each patient receives four weeks of treatment with either BGF or FUV followed by a on...
Eligibility Criteria
Inclusion
- COPD diagnosis confirmed by spirometry (post-bronchodilator FEV1/FVC \< 70%)
- Aged 40-80 years
- Smoking 10 pack-years or more
- Postbronchodilator FEV1 \< 80%
Exclusion
- History of COPD exacerbation within 3 months
- Asthma, bronchiectasis, pulmonary fibrosis
- Inability to perform spirometry, impulse oscillometry, or 6-minute walk test
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT06905483
Start Date
April 1 2025
End Date
March 31 2026
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Narongkorn Saiphoklang
Pathum Thani, Changwat Pathum Thani, Thailand, 12120